Vertex Pharmaceuticals' New Drugs Are Gaining Ground. Is That Enough for Investors?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 36,870 | $19,276,180 | -2% | 0.39% |
| 2. | Motley Fool Asset Management Bryan Hinmon | 17,753 | $9,281,446 | +3% | 0.35% |
| 3. | Sivik Global Healthcare Krishen Sud | 10,500 | $5,489,505 | +5% | 3.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $389.95 | 5,710 | $2,226,614.50 | 115,968 | 2025-08-06 | Filing | |
| $389.08 | 4,290 | $1,669,153.20 | 110,258 | 2025-08-06 | Filing | |
| $389.84 | 3,366 | $1,312,201.44 | 45,000 | 2025-08-06 | Filing | |
| $389.36 | 1,634 | $636,214.24 | 41,634 | 2025-08-06 | Filing | |
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $524.99 | 1,500 | $787,485.00 | 45,321 | 2026-07-02 | Filing | |
| $519.00 | 1,541 | $799,779.00 | 11,001 | 2026-07-02 | Filing | |
| $502.71 | 828 | $416,243.88 | 19,131 | 2026-07-01 | Filing | |
| $482.50 | 596 | $287,570.00 | 15,337 | 2026-06-26 | Filing | |
| $462.17 | 1,020 | $471,413.40 | 15,933 | 2026-06-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,219,311 | $637,467,984 | 0.62% | |
| 2. | 428,835 | $224,199,228 | 0.27% | |
| 3. | 388,770 | $203,252,844 | 1.18% | |
| 4. | 281,148 | $146,986,986 | 0.12% | |
| 5. | 202,800 | $106,225,470 | 0.53% |
News See All
Andrew Hill Investment Fund Sees More Growth Ahead for Vertex (VRTX): Here’s Why
Andrew Hill Investment Advisors recently released its third-quarter 2026 investor letter. A copy of the letter can be downloaded here.
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage.
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals.
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
On July 29, AbCellera Biologics Inc.
One Company's Clinical Miss Is Another's Moat: Vertex Rallies as Sionna's CF Bet Collapses
Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc.
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
Shares of American biotech company Vertex Pharmaceuticals ($VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics ($SION) reporte...
Options Volatility and Implied Earnings Moves Today, August 03, 2026
Today, several major companies are expected to report earnings: 3D Systems (DDD), Clorox (CLX), ON Semiconductor (ON), Oneok (OKE), Tyson Foods (TS...
10 Best QQQ Stocks to Invest in
In this article, we will discuss the 10 Best QQQ Stocks to Invest in.
Hedge Fund Resource Center